©3sat
Documentary | 2022 | 3sat, ZDFinfo [de] | Economy, Nature-Environment | Germany
Main data
| Director | Patrick Zeilhofer, Volker Wasmuth |
|---|---|
| Production | Die Medienmacher, Blue Moon Media GmbH [de] |
Project data
| Length of movie | 44min |
|---|
Brief synopsis
The deal of the century: In 2016, the Bayer Group buys the U.S. seed producer Monsanto for more than $60 billion, and with it the weed killer glyphosate. An expensive mistake?
Numerous lawsuits are pending against Bayer in the USA. U.S. customers are accusing Bayer of causing their cancer with glyphosate and are demanding compensation. Bayer denies the accusations. But the damage is there: Image problems, millions in compensation and share price losses.
The biggest deal in the company's history turned into the biggest debacle. With the takeover, Bayer CEO Werner Baumann creates an agricultural giant: Business is booming. But the Monsanto takeover keeps bringing new trouble. Now shareholders in Germany are also suing the company, accusing Bayer of not having provided sufficient information about the economic risks involved in the Monsanto takeover. German investors feel cheated out of dividend payments. Did Bayer management underestimate the risks of the purchase? Has confidence in the Group been damaged in the long term?
The authors Volker Wasmuth and Patrick Zeilhofer meet desperate cancer patients and angry investors. They meet managers and economists and want to know: Is the Monsanto deal really a failed deal of the century?
(3sat makro)
Numerous lawsuits are pending against Bayer in the USA. U.S. customers are accusing Bayer of causing their cancer with glyphosate and are demanding compensation. Bayer denies the accusations. But the damage is there: Image problems, millions in compensation and share price losses.
The biggest deal in the company's history turned into the biggest debacle. With the takeover, Bayer CEO Werner Baumann creates an agricultural giant: Business is booming. But the Monsanto takeover keeps bringing new trouble. Now shareholders in Germany are also suing the company, accusing Bayer of not having provided sufficient information about the economic risks involved in the Monsanto takeover. German investors feel cheated out of dividend payments. Did Bayer management underestimate the risks of the purchase? Has confidence in the Group been damaged in the long term?
The authors Volker Wasmuth and Patrick Zeilhofer meet desperate cancer patients and angry investors. They meet managers and economists and want to know: Is the Monsanto deal really a failed deal of the century?
(3sat makro)